semaglutide linked to cancer Disproportionality analysis of semaglutide-associated bile-duct cancer: A vigibase study | Indian Journal of Gastroenterology Multiple studies now suggest that

Why choose JuvdermVolbella XC filler

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

Messing with these levels can lead to some really serious problems such as abnormal heart rhythms, muscle problems, seizures, confusion and coma

So what happens if you get pregnant unexpectedly while on treatment